News

FDA grants orphan drug designation to Ketarx for Rett syndrome

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Ketarx (racemic ketamine) for treating Rett Syndrome. The designation is awarded to products that show promise to prevent, diagnose, or treat rare diseases. Incentives for developers include seven years of market exclusivity after approval, potential…

Rett Syndrome Research Trust Helping to Advance HRP-12975

The Rett Syndrome Research Trust (RSRT) is supporting ongoing studies of HRP-12975, an investigational therapy for Rett syndrome, using mouse models of the disease. HRP-12975, being developed by Herophilus, is reported to be the first small molecule therapy with the potential to reverse MECP2 gene deficiency, the…

Study: Girls With Rett Syndrome Display Poor Sleep Continuity

Girls with Rett syndrome caused by MECP2 gene mutations have increased deep sleep and reduced rapid eye movement (REM) sleep, a study shows.  The sleep patterns are generally similar across the patients’ genetic and clinical, or disease severity, characteristics. However, increased hand disability was associated with a…

MECP2 Changes Dictate Nerve Cell Structure and Function in Study

Nerve cells derived from Rett syndrome patients showed alterations in structure, function, and network connectivity that depend on the severity of MECP2 genetic changes that cause the condition, a study revealed. Nerve cells from a rare atypical Rett patient with mild disease and preserved speech had similar core structural…

Vezbi Community Super App Donates $500,000 to IRSF

As part of its Project Seva, Vezbi Community Super App is supporting the International Rett Syndrome Foundation (IRSF) through a $500,000 equity donation and the creation of tailored microapps for the Rett syndrome community. The community-focused Super App was created to consolidate and organize all life aspects…

Rett Syndrome Research Included in $6.9M CIHR Funding

A study on the brain’s molecular anomalies in Rett Syndrome received $100,000 in funding from the Canadian Institutes of Health Research (CIHR). The research will be conducted for a year by the team of Mojgan Rastegar, PhD, at the University of Manitoba, Canada. It’s one of six studies from…